Physician profile
Mohammed Shareef
NPI 1619112042
$1,455.98
in general payments reported to CMS, 2019-2025
27 companies · $241 in 2025
The $241 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2021: $44.50 · 2022: $169 · 2023: $18.17 · 2024: $472 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $730.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $152.78 | 2019-2024 | Opdualag, Krazati |
| Janssen Biotech, INC. | $108.94 | 2019-2024 | Rybrevant |
| Novartis Pharmaceuticals Corporation | $101.87 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2022 | |
| Genzyme Corporation | $95.61 | 2024-2025 | |
| Caris Mpi, INC. | $80.47 | 2025 | Mi Cancer Seek |
| Incyte Corporation | $65.42 | 2019-2025 | Jakafi, Zynyz, Monjuvi |
| Daiichi Sankyo INC. | $58.19 | 2024 | Enhertu |
| Amgen INC. | $55.80 | 2019 | |
| Sirtex Medical INC | $55.48 | 2022 | |
| Merck Sharp & Dohme LLC | $54.35 | 2019-2024 | Keytruda |
| Regeneron Healthcare Solutions, INC. | $52.91 | 2021-2024 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $52.88 | 2021-2024 | |
| Astellas Pharma US INC | $48.42 | 2024-2025 | Xtandi, Padcev |
| Pharmacyclics LLC, An Abbvie Company | $46.08 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $45.21 | 2019-2024 | |
| Taiho Oncology, INC. | $44.15 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $41.08 | 2019-2024 | Onivyde |
| Celgene Corporation | $34.98 | 2019-2025 | Reblozyl |
| Abbvie INC. | $30.66 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.81 | 2019 | |
| Puma Biotechnology, INC. | $23.84 | 2024 | |
| Array Biopharma INC | $22.96 | 2019 | |
| Lilly USA, LLC | $21.52 | 2019 | |
| Eisai INC. | $13.45 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $12.27 | 2019 | |
| Clovis Oncology, INC. | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Shareef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.